Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial
James Chih‐Hsin Yang(National Taiwan University Hospital), Tibor Csőszi, Naveen S. Basappa, Xavier Quantin(Inserm), Emmanuel de la Mora Jimenez(Instituto Jalisciense de Cancerología), Lorenzo Livi(European Society for Sexual Medicine), Ayman Samkari(Merck & Co., Inc., Rahway, NJ, USA (United States)), Corina E. Dutcus(Eisai (United States)), Nuri Karadurmuş(Sağlık Bilimleri Üniversitesi), Diego Moran Ortiz, P. Koralewski(Unknown), Zachary Zimmer(Merck & Co., Inc., Rahway, NJ, USA (United States)), Shunichi Sugawara(Sendai Kousei Hospital), Julia Dudnik(Soroka Medical Center), Jong-Seok Lee(Seoul National University Bundang Hospital), Niyati Bhagwati(Merck & Co., Inc., Rahway, NJ, USA (United States)), Chinyere E. Okpara(Eisai (United Kingdom)), Tarek Mekhail(AdventHealth Orlando), Baohui Han(Shanghai Jiao Tong University)
Cited by 55
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k